SELLAS Life Sciences Group (SLS) News Today

$1.54
-0.09 (-5.52%)
(As of 04/24/2024 ET)
SourceHeadline
seekingalpha.com logoSellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout
seekingalpha.com - April 19 at 3:11 PM
msn.com logoSELLAS Life Sciences Group files for $200M mixed shelf
msn.com - March 28 at 7:32 PM
globenewswire.com logoSELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
globenewswire.com - March 28 at 4:05 PM
markets.businessinsider.com logoBuy Rating for SELLAS Life Sciences Amid Positive AML Study Results and Strengthened Financials
markets.businessinsider.com - March 27 at 10:54 PM
markets.businessinsider.com logoSELLAS Phase 2a Study Of SLS009 In R/r AML Positive; Updates Phase 3 REGAL Study
markets.businessinsider.com - March 26 at 10:33 AM
globenewswire.com logoSELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
globenewswire.com - March 26 at 7:35 AM
wsj.com logoSELLAS Life Sciences Group Inc.
wsj.com - March 21 at 3:15 PM
globenewswire.com logoSELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
globenewswire.com - March 19 at 4:05 PM
globenewswire.com logoSELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
globenewswire.com - March 19 at 8:47 AM
marketwatch.com logoSellas Life Sciences Shares Drop 31% After Direct Offering Prices
marketwatch.com - March 16 at 2:16 PM
msn.com logoGeron, Graphite Bio, Immuneering among healthcare movers
msn.com - March 15 at 10:20 AM
msn.com logoSELLAS Life Sciences looks to raise $20M in a direct offering
msn.com - March 15 at 10:20 AM
markets.businessinsider.com logoSellas Announces $20 Mln Registered Direct Offering, Concurrent Private Placement
markets.businessinsider.com - March 15 at 10:20 AM
finance.yahoo.com logoSELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
finance.yahoo.com - March 15 at 9:14 AM
globenewswire.com logoSELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
globenewswire.com - March 15 at 9:00 AM
seekingalpha.com logoAadi Bioscience Q4 2023 Earnings Preview
seekingalpha.com - March 12 at 12:49 PM
investing.com logoSellas Life Sciences Group Inc (SLS)
investing.com - March 10 at 5:06 AM
finanznachrichten.de logoSELLAS Life Sciences Group, Inc.: SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
finanznachrichten.de - March 9 at 3:43 PM
globenewswire.com logoSELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
globenewswire.com - March 8 at 8:00 AM
finance.yahoo.com logoSLS Mar 2024 4.000 put
finance.yahoo.com - March 7 at 11:22 PM
finance.yahoo.com logoSELLAS Life Sciences Group, Inc. (SLS)
finance.yahoo.com - March 1 at 3:52 PM
globenewswire.com logoSELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
globenewswire.com - March 1 at 8:30 AM
globenewswire.com logoSELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
globenewswire.com - February 29 at 8:00 AM
morningstar.com logoSELLAS Life Sciences Group Inc
morningstar.com - February 22 at 1:53 PM
ca.finance.yahoo.com logoSLS Feb 2024 0.500 call
ca.finance.yahoo.com - February 16 at 12:21 AM
finanznachrichten.de logoSELLAS Life Sciences Group, Inc.: SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
finanznachrichten.de - February 6 at 1:04 PM
finance.yahoo.com logoSELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
finance.yahoo.com - February 6 at 8:48 AM
news.yahoo.com logoTesla sued for allegedly mishandling hazardous waste in California for years
news.yahoo.com - February 1 at 8:02 PM
finance.yahoo.com logoSELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
finance.yahoo.com - January 25 at 9:04 AM
msn.com logoSellas Life Sciences gains on securing orphan drug status for r/r PTCL treatment
msn.com - January 11 at 8:16 AM
markets.businessinsider.com logoBuy Rating Affirmed for SELLAS Life Sciences Amidst Promising Drug Development and Strategic Financing
markets.businessinsider.com - January 10 at 6:13 PM
msn.com logoSellas Life Sciences gains after leukemia therapy gets FDA fast track status
msn.com - January 9 at 10:22 AM
finance.yahoo.com logoSELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients
finance.yahoo.com - January 9 at 8:45 AM
markets.businessinsider.com logoSELLAS Life Sciences Prices Share Offering To Raise $9 Mln; Stock Tanks 35%
markets.businessinsider.com - January 4 at 1:48 PM
finance.yahoo.com logoSELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering
finance.yahoo.com - January 4 at 9:29 AM
msn.com logoWhy Is Sellas Life Sciences (SLS) Stock Down 25% Today?
msn.com - January 4 at 8:47 AM
msn.com logoSELLAS Life Sciences announces launch of proposed public offering
msn.com - January 4 at 5:12 AM
markets.businessinsider.com logoSELLAS Life Sciences Reports Proposed Public Offering
markets.businessinsider.com - January 3 at 11:05 PM
finanznachrichten.de logoSELLAS Life Sciences Group, Inc.: SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones
finanznachrichten.de - January 3 at 12:28 PM
msn.com logoSELLAS provides corporate updates, shares up premarket
msn.com - January 3 at 12:28 PM
finance.yahoo.com logoSELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones
finance.yahoo.com - January 3 at 8:04 AM
finance.yahoo.com logoSELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
finance.yahoo.com - December 27 at 9:27 AM
finanznachrichten.de logoSELLAS Life Sciences Group, Inc.: SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
finanznachrichten.de - December 21 at 10:53 AM
markets.businessinsider.com logoSellas Life Sciences Group Receives Orphan Drug Designation For SLS009 For Treatment Of PTCL
markets.businessinsider.com - December 21 at 10:53 AM
finance.yahoo.com logoSELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
finance.yahoo.com - December 21 at 10:52 AM
finance.yahoo.com logoSELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia
finance.yahoo.com - December 14 at 9:25 AM
finance.yahoo.com logoSELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET
finance.yahoo.com - December 13 at 8:44 AM
finance.yahoo.com logoSELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia
finance.yahoo.com - December 4 at 9:06 AM
markets.businessinsider.com logoAnalysts’ Top Healthcare Picks: Olema Pharmaceuticals (OLMA), SELLAS Life Sciences Group (SLS)
markets.businessinsider.com - December 1 at 12:22 AM
finance.yahoo.com logoSELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia
finance.yahoo.com - November 29 at 10:41 AM
Get SELLAS Life Sciences Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.

The system that called 2023’s top 7 stocks is at it again… (Ad)

Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.

Just follow this link here!

SLS Media Mentions By Week

SLS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SLS
News Sentiment

0.00

0.44

Average
Medical
News Sentiment

SLS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SLS Articles
This Week

1

1

SLS Articles
Average Week

Get SELLAS Life Sciences Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:SLS) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners